Athenex, Inc. filed a notice for the selection of Successful Bidder in the US Bankruptcy Court for the sale of substantially all its assets of Athenex Pharmaceutical Division, LLC on June 22, 2023. As a result of the auction conducted on June 21, 2023, debtor has identified two prevailing purchasers, Sagent Pharmaceuticals for a purchase price of $14 million and Oaktree Strategic Credit Asset Holdings, LLC, and Oaktree fund Administration, LLC for a credit bid of $20 million. Avenacy Inc. is acting as back-up bidder for a purchase price of $13.70 million.